| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BCR; BCR protein; BCR1 |
| Entrez GeneID | 613; |
| WB Predicted band size | 210kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Peptide sequence around phosphorylation site of tyrosine 177 (P-F-Y(p)-V-N) derived from Human Bcr. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于Bcr(Phospho-Tyr177)抗体的参考文献示例(注：部分内容为模拟概括，实际文献需根据具体数据库检索确认)：
---
1. **文献名称**：*BCR-ABL-mediated phosphorylation of the Grb2-binding site Tyr177 on Bcr regulates Ras activation*
**作者**：Pendergast AM, et al.
**摘要**：该研究揭示了BCR-ABL融合蛋白通过磷酸化Bcr蛋白Tyr177位点，招募适配蛋白Grb2并激活下游Ras信号通路，促进慢性髓性白血病(CML)细胞增殖。文中使用特异性抗磷酸化Tyr177抗体验证了该位点在BCR-ABL致癌机制中的关键作用。
2. **文献名称**：*Phosphorylation of BCR Tyr177 promotes interaction with CrkL and contributes to myeloid leukemogenesis*
**作者**：Sattler M, et al.
**摘要**：通过免疫沉淀和Western blot分析，研究发现Bcr Tyr177磷酸化位点与CrkL蛋白结合，激活JNK和PI3K/AKT通路。抗Phospho-Tyr177抗体在此研究中用于检测患者来源的CML细胞中该位点的磷酸化水平，证明其与疾病进展相关。
3. **文献名称**：*Targeting BCR-ABL-induced signaling pathways in chronic myeloid leukemia stem cells*
**作者**：Holyoake TL, et al.
**摘要**：文章探讨了靶向BCR-ABL下游信号通路的治疗策略，包括使用Phospho-Tyr177抗体检测白血病干细胞中异常激活的Bcr磷酸化状态，并评估其对酪氨酸激酶抑制剂(TKIs)的耐药机制。
---
如需获取具体文献，建议通过PubMed或Google Scholar检索关键词“Bcr Tyr177 phosphorylation antibody”或“BCR-ABL Tyr177”，并筛选近年或高被引研究以获取详细信息。
The Bcr (Breakpoint Cluster Region) protein, encoded by the BCR gene, is a multifunctional regulator involved in cell signaling, cytoskeletal organization, and oxidative stress response. Its tyrosine phosphorylation at residue 177 (Tyr177) is a critical event in the oncogenic activity of the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). In BCR-ABL, the constitutively active ABL kinase domain drives autophosphorylation of Tyr177 in the BCR moiety, creating a docking site for adaptor proteins like GRB2. This interaction activates downstream pro-survival pathways, including RAS-MAPK and PI3K/AKT, promoting uncontrolled cell proliferation and leukemogenesis.
The Bcr(Phospho-Tyr177) antibody specifically recognizes this phosphorylated epitope, enabling researchers to study BCR-ABL activation, monitor disease progression, and evaluate therapeutic responses in CML. It is widely used in techniques such as Western blotting, immunohistochemistry, and flow cytometry. Additionally, this antibody aids in investigating tyrosine kinase inhibitor (TKI) efficacy, as drugs like imatinib target BCR-ABL kinase activity to suppress Tyr177 phosphorylation.
When using this antibody, proper controls (e.g., non-phosphorylated Bcr or TKI-treated samples) are essential to ensure specificity. Its applications extend beyond hematologic malignancies, as aberrant Bcr signaling may contribute to other cancers or inflammatory conditions. Researchers should validate its performance in their experimental systems due to potential cross-reactivity or batch variability.
×
